Peptide record

TPDB02171

ACE inhibitor (from bovine a-La) ACE inhibitors Antihypertensive Antioxidant standard
3 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB02171
ACE inhibitor (from bovine a-La)
ACE inhibitors Antihypertensive Antioxidant
Cardiometabolic peptides Functional / health-promoting peptides
Peptipedia AHTPDB AHTpin AODB Multi-AOP
standard
No
A 3-aa standard-residue multi-activity (ACE inhibitors, Antihypertensive, and Antioxidant) peptide sequence curated from Peptipedia, AHTPDB, AHTpin, and other sources, with an available 3D structural model.
Sequence
YGL
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C17H25N3O5
ARNDCEQHIKMFPSTWV
GLY
351.40
5.94
0
0
2
-0
-1.91
0.700
130.00
Mammalian: 2.8 hour Yeast: 10 min E.coli: 2 min
1490
4.24
1
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
0
I
1
L
0
K
0
M
0
F
0
P
0
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 1 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
3 reviewed residue count
C17H25N3O5 sequence-only estimate (linear, free termini)
351.40 sequence-only estimate (linear, free termini)
5.94 sequence-only estimate (linear, free termini)
-0 sequence-only estimate (linear, free termini)
-1.91 sequence-only estimate (linear, free termini)
0.700 sequence-only estimate (linear, free termini)
351.3965 Activity
351.1788 Activity
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
ACE inhibitors
409.00 µM
ACE inhibitor
ah

Source & Reference

NA
Pihlanto-Leppala A. et al.
Angiotensin I-converting enzyme inhibitory properties of whey protein digests: concentration and characterization of active peptides.J. Dairy Res., 67, 53-64
2000
Journal

Other

3
BIOPEP-UWM database of bioactive peptides SMILES: [H][C@](N)(Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@]([H])(CC(C)C)C(O)=O InChI=1S/C17H25N3O5/c1-10(2)7-14(17(24)25)20-15(22)9-19-16(23)13(18)8-11-3-5-12(21)6-4-11/h3-6,10,13-14,21H,7-9,18H2,1-2H3,(H,19,23)(H,20,22)(H,24,25)/t13-,14-/m0/s1 InChIKey=KCPFDGNYAMKZQP-KBPBESRZSA-N EC50(IC50)= 1552uM. from: Meisel H., Walsh D. J., Murray B., FitzGerald R. J.(2006). ACE inhibitory peptides. in: Nutraceutical proteins and peptides in health and disease. Mine Y., Shahidi F. (Eds.), CRC Taylor & Francis Group, Boca Raton, London, New York, 269-315.
Evidence 2 Activity

Activity

IC50
Antihypertensive
409.00 µM
ACE inhibitor
ah

Source & Reference

AHTPDB
Pihlanto-Leppala A. et al.
Angiotensin I-converting enzyme inhibitory properties of whey protein digests: concentration and characterization of active peptides.J. Dairy Res., 67, 53-64
2000
Journal

Other

Source Activity Label Source Definition
Antihypertensive
AHTPDB manually curated experimentally validated antihypertensive peptide annotation.
3
BIOPEP-UWM database of bioactive peptides SMILES: [H][C@](N)(Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@]([H])(CC(C)C)C(O)=O InChI=1S/C17H25N3O5/c1-10(2)7-14(17(24)25)20-15(22)9-19-16(23)13(18)8-11-3-5-12(21)6-4-11/h3-6,10,13-14,21H,7-9,18H2,1-2H3,(H,19,23)(H,20,22)(H,24,25)/t13-,14-/m0/s1 InChIKey=KCPFDGNYAMKZQP-KBPBESRZSA-N EC50(IC50)= 1552uM. from: Meisel H., Walsh D. J., Murray B., FitzGerald R. J.(2006). ACE inhibitory peptides. in: Nutraceutical proteins and peptides in health and disease. Mine Y., Shahidi F. (Eds.), CRC Taylor & Francis Group, Boca Raton, London, New York, 269-315.
Evidence 3 Activity

Activity

Antioxidative activity
Antioxidant

Source & Reference

AODB
DFBP
Additional Detail Fields 1 fields
3